Accordingly, our group has shown that combining XVir-N-31 with CDK4/6i enhances its anti-tumor effects by increasing virus production, genome replication, particle formation, and cancer cell-killing, as shown in vitro and in vivo using humanized murine models13,14,35. Here, CDK4 is linked to cancer.